Riskpilot← Back to searchSign inGet full accessExScale Biospecimen Solutions AB
ABBankruptOrg 5568926090Other research and experimental development on natural sciences and engineering · NACE 7219Est. 20123 employees
Revenue 2018
SEK 1M
-15% vs 2017
EBITDA margin
-709.8%
-23% vs 2017
Equity ratio
52.4%
Financial strength
Net profit 2018
SEK -10,6M
-63% vs 2017
| Revenue | SEK 1M | -15% |
| EBITDA | SEK -7,2M | -23% |
| Net profit | SEK -10,6M | -63% |
| Total assets | SEK 4,7M | -67% |
| Equity | SEK 2,5M | -79% |
| Employees | 3 | — |
Legal name
ExScale Biospecimen Solutions AB
Org number
5568926090
Legal form
Aktiebolag
NACE code
7219 · Other research and experimental development on natural sciences and engineering
Founded
8 maj 2012
Share capital
SEK 0
Employees
3 (FTE)
VAT registered
No
Audit selected
No
Last report
2018-12-31
Financial year
January – December
Company purpose
Bolaget skall bedriva utveckling, tillverkning och försäljning av utrustning, reagens och tjänster för extraktion av nukleinsyror samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|
| Revenue | — | 778 | 1 203 | 1 017 |
| Staff expenses | — | — | — | — |
| EBITDA | −1 181 | −3 303 | −5 855 | −7 219 |
| Depreciation & amort. | −51 | −277 | −524 | −1 938 |
| EBIT | −1 232 | −3 580 | −6 379 | −9 157 |
| Net financials | −47 | −98 | −99 | −1 405 |
| Profit before tax | −1 280 | −3 678 | −6 478 | −10 562 |
| Tax | −0 | −0 | −0 | −0 |
| Net profit | −1 280 | −3 678 | −6 478 | −10 562 |
| Item | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|
| Total assets | 3 321 | 21 392 | 14 445 | 4 736 |
| Equity | 1 866 | 18 264 | 11 785 | 2 483 |
| Long-term debt | 1 000 | 1 571 | 1 286 | 1 091 |
| Short-term debt | 455 | 1 557 | 1 374 | 1 162 |
| Total debt | 1 455 | 3 128 | 2 660 | 2 253 |
EBITDA margin
-709.8%
This company
15.8%
Market median
-4592% vs market
20152018
Equity ratio
52.4%
This company
38.2%
Market median
+37% vs market
20152018
Return on equity
-425.4%
This company
18.4%
Market median
-2412% vs market
20152018
Net profit margin
-1038.5%
This company
8.1%
Market median
-12921% vs market
20152018
Asset turnover
0.21×
This company
1.12×
Market median
-81% vs market
20152018
Debt / equity
0.91×
This company
0.62×
Market median
+47% vs market
20152018
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
KL Audit | Audit | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ExScale Biospecimen Solutions AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karl Leonard Daun | Audit | 0 companies |
| Lucy Anne Mathot | Deputy Board Member | 0 companies |
| Sten Ivar Gunnar Dahlborg | Board of Directors | 0 companies |
| Liang Weimin | Board of Directors | 0 companies |
| John Allan Asp | Board of Directors | 0 companies |
| Tapela Theresa Mavudzi-Dahlborg | Deputy Board Member | 0 companies |
| Andrew Francis Browning | Deputy Board Member | 0 companies |
| Simon James Grant | Board of Directors | 0 companies |
| Carl Tobias Sjöblom | Chairman | 0 companies |
| Edmund Su Mingda | Deputy Board Member | 0 companies |